4D Molecular Therapeutics, Inc. (FDMT)
| Previous Close | 25.39 |
| Open | 25.35 |
| Bid | 26.38 x 100 |
| Ask | 26.53 x 100 |
| Day's Range | 24.93 - 26.50 |
| 52 Week Range | 9.44 - 36.25 |
| Volume | |
| Avg. Volume | 1,215,924 |
| Market Cap | 1.354B |
| Beta (5Y Monthly) | 2.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.58 |
| Earnings Date | May 08, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.20 |
Zacks4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
4D Molecular Therapeutics (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswire4DMT Announces Presentations at ARVO 2024 Annual Meeting
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the 2
GuruFocus.com4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares
On April 1, 2024, Chief Legal Officer Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) according to a recent SEC Filing.
